This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Illumina Announces Phasing Analysis Service For Human Whole-Genome Sequencing

Stocks in this article: ILMN

Illumina, Inc. (NASDAQ:ILMN) today announced the availability of its Phasing Analysis Service, provided by the company’s FastTrack Services lab through the Illumina Genome Network (IGN). The new sample-to-answer service delivers human whole-genome phase information, empowering gene mapping studies with a more comprehensive view of genomic variation. With phase data, researchers can better understand the effect of genotype on phenotype and variant interaction within a gene.

Conventionally, whole-genome sequencing generates a single consensus sequence without assigning variants to specific homologous chromosomes. Phase information, however, can identify segments of connected variants, facilitating ancestry determination in population studies. Further, in instances where two potentially deleterious variants occur in a gene, knowing how these variants impact the function of one or both copies of the gene is useful in identifying genetic causes of disease. Illumina’s Phasing Analysis Service reduces reliance on statistical inference methods and availability of trios, thereby delivering more accurate phase information at a fraction of the cost of conventional methods.

“We are thrilled to be the first company to offer the research community this comprehensive human whole-genome sequencing and phasing service,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business. “Customers who participated in the beta testing used the service for a diverse range of applications, from human population studies to the identification of variants causing rare disease. Early customer feedback has been overwhelmingly positive.”

Illumina gained access to the synthetic long read technology that enables human whole-genome phasing through its acquisition of Moleculo, Inc. announced in January 2013. Sample preparation kits for generating synthetic long reads and human phasing data are in development.

The new Phasing Analysis Service is available for immediate ordering as an add-on to the IGN Whole-Genome Analysis Service, delivering results within twelve weeks. For more information, please visit www.illumina.com/phasedsequencing.

About Illumina

Illumina ( www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs